Mobile

An exploratory Phase II, multicenter, open-label trial evaluating the activity and tolerability of of FK228 in androgen independent metastatic prostate cancer patients with a rising PSA

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-001576-13

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this trial is to evaluate the activity of FK228 in patients with metastatic prostate cancer who have developed a rising PSA while undergoing hormonal therapy. Activity will be measured as the rate of disease control (complete response [CR], partial response [PR], or stable disease [SD] for at least 6 months).

Critère d'inclusion

  • metastatic prostate cancer

Liens